A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
NCT ID: NCT00316758
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
259 participants
INTERVENTIONAL
2006-02-28
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
GK Activator (2)
Escalating doses bid
Metformin
As prescribed, in patients who were in study BM18249
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GK Activator (2)
Escalating doses bid
Metformin
As prescribed, in patients who were in study BM18249
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients considered by the investigator to be suitable for long term treatment with GK Activator (2).
Exclusion Criteria
* women who are pregnant, breast-feeding or not using adequate contraceptive methods.
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chula Vista, California, United States
Chula Vista, California, United States
Los Angeles, California, United States
Spring Valley, California, United States
West Hills, California, United States
Hollywood, Florida, United States
Kissimmee, Florida, United States
Atlanta, Georgia, United States
Arkansas City, Kansas, United States
Butte, Montana, United States
Binghamton, New York, United States
Fayetteville, North Carolina, United States
Statesville, North Carolina, United States
Winston-Salem, North Carolina, United States
Springdale, Ohio, United States
Oklahoma City, Oklahoma, United States
Medford, Oregon, United States
Beaver, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Memphis, Tennessee, United States
Federal Way, Washington, United States
Renton, Washington, United States
Camperdown, , Australia
Heidelberg, , Australia
Dimitrovgrad, , Bulgaria
Pleven, , Bulgaria
Rousse, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Vancouver, British Columbia, Canada
London, Ontario, Canada
Montreal, Quebec, Canada
Zagreb, , Croatia
Bammental, , Germany
Berlin, , Germany
Essen, , Germany
Giessen, , Germany
Görlitz, , Germany
Hamburg, , Germany
Künzing, , Germany
Nuremberg, , Germany
Tann, , Germany
Guatemala City, , Guatemala
Budapest, , Hungary
Győr, , Hungary
Kecskemét, , Hungary
Chihuahua City, , Mexico
Cuernavaca, , Mexico
Durango, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Bialystok, , Poland
Gdansk, , Poland
Gorzów, , Poland
Krakow, , Poland
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NC19794
Identifier Type: -
Identifier Source: org_study_id